Sub Heading

Clinical Trials Details

A randomized, double-blind, placebo-controlled phase 3 study of Bemarituzumab plus chemotherapy versus placebo plus chemotherapy in subjects with previously untreated advanced gastric or gastroesophageal junction cancer with FGFR2b Overexpression

IRB Protocol Number
Amgen 20210096 (FORTITUDE-101)

Clinical Trial Categories

  • Gastric Cancer
Contact
Clinical Trials at 910-715-2200
How to Participate

Eligibility: Men and women age 18 and older with unresectable, locally advanced, or metastatic histologically documented gastric or GEJ adenocarcinoma.

Contact Us

For more information on participating in a clinical trial, contact us at 910-715-2200 or talk to your doctor.